This technology platform integrates multi-omics and liquid biopsy data of pancreatic cancer, combined with in silico analysis and patient-derived models, to precisely decode molecular subtypes, immune microenvironment, and drug responses. It has been clinically validated in over 400 patient cases, enabling non-invasive disease monitoring and personalized treatment decision-making, with high potential for clinical translation and commercialization.

Pancreatic cancer is an aggressive malignancy with poor prognosis, high molecular heterogeneity, and strong immunosuppression, limiting traditional therapy efficacy. Our team developed a multi-omics-guided precision oncology platform integrating multi-omics analysis, liquid biopsy, tumor microenvironment profiling, and novel therapies. Validated in over 400 patients, this platform overcomes diagnostic, therapeutic, and monitoring challenges, advancing precision medicine for pancreatic cancer.

This platform integrates cfDNA and exosome liquid biopsy for tumor monitoring and treatment response, with companion diagnostic potential. Using multi-omics and AI, it builds drug sensitivity and prognosis models for personalized therapy. Gene therapies offer high specificity and low toxicity. Applied in 400+ cases, it expands to other GI cancers and smart medicine, with robust data management and cross-disciplinary collaboration, advancing commercialization and Taiwan’s biotech growth.